{"brief_title": "An Open-Label Extension Study of NGX-4010 for the Treatment of Neuropathic Pain", "brief_summary": "This study is an open-label, multicenter, extension study for subjects who completed NeurogesX Study C111 and received treatment with NGX-4010 (Capsaicin Patch) within 12 weeks (up to +7days) before entry into Study C114", "condition": "Polyneuropathies", "intervention_type": "Drug", "intervention_name": "Capsaicin Dermal Patch", "criteria": "Key Eligibility Criteria: - Must have completed NeurogesX Study C111 and received treatment with NGX-4010 (Capsaicin Patch) within 12 weeks (up to +7 days) before entry into Study C114. - Demonstrated adherence to protocol requirements during Study C111, and willing and able to comply with protocol requirements for the duration of the study participation. - Must not have had any serious adverse experience since enrollment in Study C111, whether or not considered to be study drug-related. - Must have intact skin at the treatment area. - Must be prepared to remain on the same pain medications at the same doses as before the study for the entire duration of the study (36 weeks). - Must not use topical pain medications on painful areas. - Must be at least 18 years old, not pregnant, and able to take care of self independently, with only occasional assistance if needed. - No history or current problem with substance abuse.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00089557.xml"}